DRREDDY - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | DRREDDY | Market Cap | 1,06,422 Cr. | Current Price | 1,274 ₹ | High / Low | 1,380 ₹ |
| Stock P/E | 22.9 | Book Value | 378 ₹ | Dividend Yield | 0.63 % | ROCE | 25.8 % |
| ROE | 20.3 % | Face Value | 1.00 ₹ | DMA 50 | 1,273 ₹ | DMA 200 | 1,256 ₹ |
| Chg in FII Hold | -2.35 % | Chg in DII Hold | 2.45 % | PAT Qtr | 90.6 Cr. | PAT Prev Qtr | 387 Cr. |
| RSI | 47.2 | MACD | 6.91 | Volume | 10,47,383 | Avg Vol 1Wk | 11,83,492 |
| Low price | 1,020 ₹ | High price | 1,380 ₹ | PEG Ratio | 0.47 | Debt to equity | 0.13 |
| 52w Index | 70.8 % | Qtr Profit Var | -89.3 % | EPS | 55.6 ₹ | Industry PE | 27.2 |
📊 Dr. Reddy’s Laboratories (DRREDDY) shows moderate intraday potential today. RSI at 47.2 indicates neutral momentum, while MACD is slightly positive (6.91), suggesting mild bullish sentiment. Current price (1,274 ₹) is near the 50 DMA (1,273 ₹) and above the 200 DMA (1,256 ₹), reflecting short-term stability. Volume (10,47,383) is slightly below average (11,83,492), limiting breakout potential but still providing liquidity.
💡 Optimal Buy Price: 1,270–1,280 ₹ (near support)
🎯 Profit-Taking Levels: 1,300–1,320 ₹ (short-term resistance)
🛑 Stop-Loss: 1,255 ₹ (recent low)
⏳ If already holding intraday: Exit near 1,300–1,310 ₹ if momentum weakens or if price fails to sustain above 1,280 ₹ with volume confirmation.
Positive
- Strong ROCE (25.8%) and ROE (20.3%) indicate efficient capital use.
- EPS of 55.6 ₹ supports earnings strength.
- PEG ratio of 0.47 suggests reasonable valuation relative to growth.
- DII holdings increased (+2.45%), showing strong domestic institutional support.
- 52-week performance is strong (+70.8%).
Limitation
- Quarterly PAT dropped sharply from 387 Cr. to 90.6 Cr. (-89.3%).
- FII holdings decreased (-2.35%), reflecting reduced foreign investor confidence.
- High P/E (22.9) compared to industry average (27.2) is slightly elevated.
- Volume below average, limiting intraday opportunities.
Company Negative News
- No major negative news reported, but steep decline in quarterly profits weighs on sentiment.
Company Positive News
- Strong ROCE and ROE highlight operational efficiency.
- DII inflows indicate domestic confidence in the company.
Industry
- Industry P/E at 27.2 is slightly higher than Dr. Reddy’s 22.9, suggesting fair valuation.
- Pharmaceutical sector remains resilient, supported by global demand but faces pricing and regulatory pressures.
Conclusion
✅ Dr. Reddy’s Laboratories shows moderate intraday potential with stable price action near key averages and mild bullish signals from MACD. Short-term traders may attempt a trade near 1,270–1,280 ₹ with a stop-loss at 1,255 ₹ and target exits around 1,300–1,320 ₹. Conservative traders should wait for stronger volume confirmation before entering aggressive intraday positions.